Skip to main content

Table 3 Sensitivity analysis after excluding participants on vitamin D

From: Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study

FGF23 (RU/mL) Before sodium bicarbonatea After sodium bicarbonate p-value
Taking vitamin Db
 Yes (n = 9) 217.0 (146.4–353.2)* 327.4 (231.7–410.9) 0.31
 No (n = 20) 121.2 (85.1–162.4)* 147.4 (107.0–196.5) 0.08
Taking paricalcitol
 Yes (n = 3) 353.2 (98.9–824.9)** 399.1 (327.4–410.9) 0.59
 No (n = 17) 146.4 (116.5–217.0)** 185.7 (129.9–238.4) 0.009
Increased paricalcitol dose
 Yes (n = 1)c 98.8 399.1 N/A
 No (n = 19) 155.5 (116.5–286.5) 186.4 (129.9–306.4) 0.08
Participant #16d
 Yes (n = 1) 824.9 410.9 N/A
 No (n = 19) 146.4 (98.8–248.3) 186.4 (129.9–306.4) 0.01
  1. FGF23 was expressed in median (interquartile range)
  2. Abbreviation: N/A not applicable
  3. *p-value comparing FGF23 between those taking vitamin D and those not taking vitamin D = 0.06
  4. **p-value comparing FGF23 between those taking paricalcitol and those not taking paricalcitol = 0.02
  5. aVariables for “before sodium bicarbonate” were the mean of values between the initial visit and after 2-week placebo
  6. bVitamin D used included ergocalciferol, cholecalciferol and paricalcitol
  7. cParticipant #3 had paricalcitol dose increased during the study
  8. dParticipant #16 had very a high FGF23 level at baseline